Can daily adaptive radiotherapy spare healthy tissue in prostate cancer?
NCT ID NCT06678126
First seen Sep 18, 2026 · Last updated Sep 18, 2026
Summary
Researchers are testing whether daily adaptive radiotherapy, which adjusts the radiation plan to each day's anatomy, causes fewer bladder and bowel side effects than standard radiotherapy in people with intermediate or high risk localized prostate cancer. The trial also compares two different bladder filling instructions to see if personalized guidance improves treatment. About 104 participants will receive 20 radiation treatments to the prostate and pelvic lymph nodes. The study measures side effects reported by patients over two years.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- adaptive radiotherapy and bladder filling instructions
- What this could lead to
- If adaptive radiotherapy reduces bladder and bowel side effects, it could become a preferred way to deliver radiation for prostate cancer. Custom bladder instructions might also improve treatment accuracy and comfort.
- What could go wrong
- This is a small phase 2 trial with 104 participants, so it may not show a clear difference between the techniques. Adaptive radiotherapy requires daily imaging and replanning, which can be complex and may not be widely available.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
About 104 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jan 2026
- Expected to finish
-
Jan 2035
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Male participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age ≥ 18 * Pathological diagnosis of a primary prostate adenocarcinoma * NCCN Intermediate or high risk localized prostate cancer and clinically N0 and M0 by conventional imaging * Intermediate: one or more of cT2b-T2c, PSA 10-20, or Gleason Group 2 or 3 * High: one or more of: cT3a, PSA \> 20, or Gleason Group 4 or 5. * Consented to RT with moderate hypofractionated RT to pelvic nodes (44 Gy) and prostate (60Gy) in 20 fractions using standard BC Cancer regimen * Able to complete BC Cancer POSI questionnairesWilling to attend adaptive treatment slot timing as required by treating centre. * Willing and able to have regular per protocol follow up and blood work * Feasible to start protocol treatment within 120 calendar days of participant enrolment * Continent of urine (or able to maintain continence with penile clamp/cuff during RT as needed) and able to follow bladder filling instructions. * Baseline IPSS score \< 20 at time of enrolment. * ECOG performance Status : 0-2. * Nodal risk ≥ 20% using the Memorial Sloan Kettering Nodal Risk Nomogram (https://www.mskcc.org/nomograms/prostate/pre\_op). * Negative for bone metastases on bone scan within 3 months of enrolment * No involved nodes on Abdomen and pelvic CT or pelvic MRI within 3 months of enrolment. Exclusion Criteria: * Indwelling urinary catheter. * Hip prosthesis * Prior pelvic radiotherapy * Unable to lie still on RT treatment couch for more than 30 minutes * Clinical T3b or T4 tumours * Prior transurethral resection of prostate or radical prostatectomy * Presence of a pelvic kidney. * Prior pelvic radiotherapy. * Significant urinary incontinence: ie \> 1 soaked, or 2 non-soaked pads per day. * Inflammatory bowel disease, systemic lupus erythematosis, scleroderma, or other connective tissue disorders other than rheumatoid arthritis. * Metastatic disease identified on staging investigations. * Any other serious intercurrent illness or medical condition judged by the local investigator to compromise the participant's safety, preclude safe administration of the planned protocol treatment, or prevent the participant from being managed according to the protocol guidelines * Potentially fertile patient who are unwilling to employ highly effective contraception
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Prostate cancer are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
BC Cancer Vancouver
RECRUITINGVancouver, British Columbia, V5Z4E6, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A scanner in the operating room could show surgeons exactly where prostate cancer remains
- New PET tracer aims to light up hidden cancer targets
- Can a radioactive tracer and MRI reveal prostate Cancer's true extent?
- Five-Fraction radiation plus hormone therapy tested against High-Risk prostate cancer
- Can a 10-Hour eating window fight cancer fatigue?
- New drug combo targets CD46 in aggressive prostate cancer